UPDATED: Eli Lilly tops up positive PhIII data for its Covid-19 antibody combo at ‘the optimal dose’
Eli Lilly has added another brick in the wall of positive data assembled for its combo antibody therapy for Covid-19.
Its BLAZE-1 Phase III study demonstrated that the combination of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg significantly reduced the risk of hospitalization and death among high-risk patients diagnosed with the disease.
Among 769 patients, researchers counted 4 events in the combo arm and 15 in the placebo group, giving them a risk reduction of 87% that topped the 70% mark tracked in an earlier study.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.